06/13/2026
JAMA published something this month I want every peptide-curious person to read 👆
The short version: peptides are about to get a lot more accessible in the US 🙌
The FDA — under HHS Secretary RFK Jr., a self-described peptide user — is preparing to:
→ Add gray-market peptides to the list of ingredients that can be sold as dietary supplements
→ Allow compounding pharmacies to resume preparing peptides banned in 2023 over safety concerns
→ Convene an advisory committee in July to review BPC-157, KPV, TB-500, MOTS-c, epitalon, and others
JAMA’s reporting raises legitimate concerns:
→ Most peptides on the market are synthesized inexpensively overseas, with no guarantee they contain what the label claims
→ Clinical trials of safety and efficacy in humans are virtually nonexistent
→ People are stacking multiple peptides with no understanding on how they interact
My honest take as a practitioner who has seen great results from peptides both personally and clinically:
Increased access will undoubtedly bring increased demand — which floods the market with low-quality product. We’re already seeing it.
Some peptides being studied show real promise — MOTS-c for sarcopenia, BPC-157 for tissue repair, SS-31 for mitochondrial function. The science is exciting. But “exciting science” and “safe to inject anything you can buy online” are not the same thing.
The question that matters most isn’t which peptide — it’s where it’s coming from, and who is helping you think through the protocol.
The wellness influencer telling you to “just try it” is not the same as a qualified practitioner who understands how peptides interact with your physiology, medications, goals, and existing health conditions.
Be curious. Be informed. Be very picky about your sources.
More coming soon on how to evaluate peptide sources.
Book a free peptide consultation (Calendly link in bio) or DM me “GLP1” for my free GLP-1 Metabolic Reset Starter Guide.